Meeting
2014 Gastrointestinal Cancers Symposium
The importance of sequence in rescheduling bevacizumab and chemotherapy administration in the first-line treatment of metastatic colorectal carcinoma (mCRC).
Authors
Leonidas Chelis
University Hospital of Alexandroupolis, Alexandroupolis, Greece
Leonidas Chelis , Nikolaos Xenidis , Kiriakos Amarantidis , Nikolaos Diamantopoulos , Anastasios L. Boutis , Triantafyllia Koukaki , Prodromos Michailidis , Evagelos Christakidis , Athanasios Chalvatzis , Dimitrios Matthaios , Savas Deftereos , Nikos Courcoutsakis , Panagiotis Prassopoulos , Stylianos Kakolyris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 617)
DOI
10.1200/jco.2014.32.3_suppl.617
Abstract #
617
Poster Bd #
E8
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
PROX: Primary resistance to oxaliplatin containing regimen in the first line treatment of metastatic colorectal carcinoma—Retrospective analysis.
First Author: Larissa Machado
Poster
2014 Gastrointestinal Cancers Symposium
Cost differential among systemic therapies for colon cancer.
First Author: Hasan Nadeem
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A meta-analysis of bevacizumab’s cardiovascular risks in patients treated for colorectal cancer.
First Author: Akshit Chitkara
Poster
2022 ASCO Gastrointestinal Cancers Symposium
QoL analysis: A randomized phase 3 study of sequential versus combination treatment in first-line chemotherapy for metastatic colorectal cancer—The C-cubed study.
First Author: Shingo Noura